Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Revenue (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Revenue for 4 consecutive years, with $861000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Revenue fell 12.77% to $861000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.8 million, a 6.46% increase, with the full-year FY2024 number at $2.6 million, down 4.42% from a year prior.
  • Revenue was $861000.0 for Q3 2025 at Orchestra BioMed Holdings, up from $836000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $1.2 million in Q1 2023 to a low of $253000.0 in Q4 2024.
  • A 4-year average of $766400.0 and a median of $861000.0 in 2025 define the central range for Revenue.
  • Peak YoY movement for Revenue: crashed 76.25% in 2023, then soared 135.56% in 2024.
  • Orchestra BioMed Holdings' Revenue stood at $1.1 million in 2022, then plummeted by 76.25% to $262000.0 in 2023, then fell by 3.44% to $253000.0 in 2024, then skyrocketed by 240.32% to $861000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Revenue are $861000.0 (Q3 2025), $836000.0 (Q2 2025), and $868000.0 (Q1 2025).